Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study

Código QR

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study

Diego Novick,1 Jihyung Hong,1 William Montgomery,2 Héctor Dueñas,3 Magdy Gado,4 Josep Maria Haro5 1Eli Lilly and Company, Windlesham, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, Australia; 3Eli Lilly de Mexico, Mexico City, Mexico; 4Eli Lilly and Company, Riyadh, Saudi Arabi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Novick D, Hong J, Montgomery W, Dueñas H, Gado M, Haro JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/021e8ad80d89430daccb3c0894f13687
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study
por: Saragoussi D, et al.
Publicado: (2017)

Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients
por: Novick D, et al.
Publicado: (2016)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick D, et al.
Publicado: (2016)

Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission
por: Charnsil C, et al.
Publicado: (2012)

Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash AI, et al.
Publicado: (2019)

Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick D, et al.
Publicado: (2016)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang J, et al.
Publicado: (2018)

Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression
por: Harada E, et al.
Publicado: (2016)

Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatment
por: Lee BH, et al.
Publicado: (2014)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada E, et al.
Publicado: (2017)

Toward an online cognitive and emotional battery to predict treatment remission in depression
por: Gordon E, et al.
Publicado: (2015)

Temperament, personality, and treatment outcome in major depression: a 6-month preliminary prospective study
por: Kudo Y, et al.
Publicado: (2016)

Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial
por: Sook Yan Lee, et al.
Publicado: (2021)

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study
por: Haro JM, et al.
Publicado: (2019)

Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?
por: Sueki A, et al.
Publicado: (2016)

Identifying Suicidal Ideation Among Chinese Patients with Major Depressive Disorder: Evidence from a Real-World Hospital-Based Study in China
por: Ge F, et al.
Publicado: (2020)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
por: Hammer-Helmich L, et al.
Publicado: (2018)

Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome
por: Valencia M, et al.
Publicado: (2015)

Remission of classic rapid cycling bipolar disorder with levothyroxine augmentation therapy in a male patient having clinical hypothyroidism
por: Chen PH, et al.
Publicado: (2015)

&nbsp;Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group)
por: Abrahamian H, et al.
Publicado: (2012)

Neuromodulation and antenatal depression: a review
por: Kim DR, et al.
Publicado: (2015)

Baseline rumination levels as a predictor of response to repetitive transcranial magnetic stimulation in major depressive disorder
por: Tian Ren Chu, et al.
Publicado: (2021)

Predictors of premature discontinuation of outpatient treatment after discharge of patients with posttraumatic stress disorder
por: Wang HR, et al.
Publicado: (2015)

Brainmarker-I: a transdiagnostic EEG biomarker predicting remission to various depression and ADHD treatments
por: Helena Voetterl, et al.
Publicado: (2021)

Clinical preference for factors in treatment of geriatric depression
por: Riepe MW
Publicado: (2014)

Outcome predictors in autism spectrum disorders preschoolers undergoing treatment as usual: insights from an observational study using artificial neural networks
por: Narzisi A, et al.
Publicado: (2015)

Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
por: Maciel A, et al.
Publicado: (2018)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
por: Saragoussi D, et al.
Publicado: (2018)

Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia
por: Wang G, et al.
Publicado: (2020)

Effect of depressive symptoms on the length of hospital stay among patients hospitalized for acute stroke in Japan
por: Sugawara N, et al.
Publicado: (2015)

Desvenlafaxine in the treatment of major depressive disorder
por: Maria Teresa C Lourenco1, et al.
Publicado: (2009)

Development and Validation of 3-Month Major Post-Stroke Depression Prediction Nomogram After Acute Ischemic Stroke Onset
por: Li G, et al.
Publicado: (2021)

Can low brain-derived neurotrophic factor levels be a marker of the presence of depression in obese women?
por: Celik Guzel E, et al.
Publicado: (2014)

Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China
por: Wang G, et al.
Publicado: (2019)

Shen-Qi-Jie-Yu-Fang has antidepressant effects in a rodent model of postpartum depression by regulating the immune organs and subsets of T lymphocytes
por: Qu M, et al.
Publicado: (2015)

Psychiatric comorbidities in patients with major depressive disorder
por: Thaipisuttikul P, et al.
Publicado: (2014)

Transcranial magnetic stimulation for the treatment of major depression
por: Janicak PG, et al.
Publicado: (2015)